Effects of atorvastatin and ticagrelor combination therapy on renal function and the levels of suppression of tumorigenicity 2 and interleukin-33 in patients with ST-segment elevation myocardial infarction.
Effects of atorvastatin and ticagrelor combination therapy on renal function and the levels of suppression of tumorigenicity 2 and interleukin-33 in patients with ST-segment elevation myocardial infarction.
复制标题
DOI：
10.1177/0300060520959502
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
Wang Y
中科院分区：
文献类型：
--
作者：
Zhang L;Hu M;Chen Y;Wang Y
我们评估了阿托伐他汀和替格瑞洛联合治疗对ST段抬高型心肌梗死（STEMI）患者肾功能以及致瘤性2（ST 2）和白细胞介素33（IL-33）抑制水平的影响。回顾性分析2015年1月至2018年3月在我院接受急诊经皮冠状动脉介入治疗的84例STEMI患者，分为对照组（n = 44）和观察组（n = 40）。对照组给予阿托伐他汀常规治疗STEMI，观察组在此基础上加用替格瑞洛。治疗后，对照组在胸痛缓解、酶水平、再灌注相关心律失常持续时间和ST段压低等临床指标方面的结局明显优于观察组。两组心脏超声指标均有所改善，但观察组左室舒张末期和收缩末期内径较对照组低，左室射血分数较对照组高。阿托伐他汀和替格瑞洛联合治疗对STEMI患者临床有效且安全，因为它降低了心肌梗死的程度，保护了心脏和肾功能，改善了炎症，并降低了不良心脏事件的发生率。
We evaluated the effects of atorvastatin and ticagrelor combination therapy on renal function and the levels of suppression of tumorigenicity 2 (ST2) and interleukin 33 (IL-33) in patients with ST-segment elevation myocardial infarction (STEMI). Eighty-four STEMI patients who underwent emergency percutaneous coronary intervention at our hospital from January 2015 to March 2018 were retrospectively analyzed and divided into a control group (n = 44) and an observation group (n = 40). The control group was treated with atorvastatin as routine STEMI treatment, whereas the observation group was concurrently administered ticagrelor. After treatment, significantly better outcomes were observed in the control group than in the observation group in terms of clinical indices, including chest pain relief, enzyme levels, duration of reperfusion-associated arrhythmia, and depression of the ST segment. Both groups exhibited improvements in cardiac ultrasound indices, whereas the observation group showed lower left ventricular end-diastolic and end-systolic diameters and higher left ventricular ejection fractions than the control group. Atorvastatin and ticagrelor combination therapy is clinically effective and safe for STEMI patients as it reduces the degree of myocardial infarction, protects the heart and renal functions, improves inflammation, and reduces adverse cardiac event incidences.
登录
查看更多内容
影响因子：
5.3
作者：
De Luca, Giuseppe;Suryapranata, Harry;de Boer, Menko-Jan
通讯作者：
de Boer, Menko-Jan
影响因子：
7.3
作者：
Sugidachi, A.;Ohno, K.;Tomizawa, A.
通讯作者：
Tomizawa, A.
DOI：
10.5414/cp201903
发表时间：
2013-10-01
影响因子：
0.8
作者：
Teng, Renli;Butler, Kathleen
通讯作者：
Butler, Kathleen
影响因子：
2.1
作者：
Chen CJ;Yang TC;Chang C;Lu SC;Chang PY
通讯作者：
Chang PY
影响因子：
1.5
作者：
Hamilton, Richard J.;Keyfes, Vadim;Banka, Sahil S.
通讯作者：
Banka, Sahil S.